In Phase A, contributors will obtain unique doses and schedules of oral ABBV-744 pill to recognize Risk-free dosing program. Extra members will be enrolled on the determined monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase C, participants https://abbv-744-brd4-inhibitor-m91346.izrablog.com/32504504/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know